| P2093 | author name string | Graybill JR | |
| | Hardin TC | |
| | Burgess DS | |
| P2860 | cites work | Positive interaction of nikkomycins and azoles against Candida albicans in vitro and in vivo | Q28316948 |
| | In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin | Q28316952 |
| | In vitro evaluation of the pneumocandin antifungal agent L-733560, a new water-soluble hybrid of L-705589 and L-731373 | Q28367886 |
| | Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis | Q28367890 |
| | In vitro antifungal and fungicidal spectra of a new pradimicin derivative, BMS-181184 | Q28368085 |
| | Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections | Q33380627 |
| | A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490) | Q34720507 |
| | Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. | Q34722375 |
| | Resistance of Candida species to fluconazole | Q35110522 |
| | Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group | Q35110598 |
| | Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B. | Q35112132 |
| | In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans | Q35116931 |
| | Use of amphotericin B with azole antifungal drugs: what are we doing? | Q35117932 |
| | Antifungal susceptibility tests | Q35562348 |
| | Increased antifungal activity of L-733,560, a water-soluble, semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesis | Q35823016 |
| | Interaction of Chemotherapy and Immune Defenses in Experimental Murine Cryptococcosis | Q36475277 |
| | Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis | Q36753389 |
| | Susceptibility of Candida albicans and other yeasts to fluconazole: relation between in vitro and in vivo studies | Q37918353 |
| | Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature | Q37983866 |
| | Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole | Q39866233 |
| | Pharmacologic modulation of interleukin-1 expression by amphotericin B-stimulated human mononuclear cells | Q39869275 |
| | Enhancement of macrophage superoxide anion production by amphotericin B | Q40086453 |
| | Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis | Q40285200 |
| | Oral azole drugs as systemic antifungal therapy | Q40796244 |
| | A Comparison of Amphotericin B Alone and Combined with Flucytosine in the Treatment of Cryptoccal Meningitis | Q41644134 |
| | Correlation between in vitro and in vivo activity of antifungal agents against Candida species | Q42283580 |
| | Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis | Q42287986 |
| | Amphotericin B induces tumor necrosis factor production by murine macrophages | Q43440468 |
| | Annulment of amphotericin B inhibition of Coccidioides immitis endospores. Effects on growth, respiration and morphogenesis | Q43491140 |
| | A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group | Q43574526 |
| | High-dose fluconazole for treatment of cryptococcal disease in patients with human immunodeficiency virus infection. The California Collaborative Treatment Group | Q43674749 |
| | Prevention of relapse of histoplasmosis with fluconazole in patients with the acquired immunodeficiency syndrome | Q44030670 |
| | Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils | Q44241025 |
| | Protective effect of human granulocyte colony stimulating factor (hG-CSF) on Candida, infections in normal and immunosuppressed mice | Q44585691 |
| | Concomitant amphotericin B therapy, granulocyte transfusions, and GM-CSF administration for disseminated infection with Fusarium in a granulocytopenic patient | Q44932195 |
| | A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group | Q45244768 |
| | Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. | Q46047518 |
| | Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? | Q46734347 |
| | Discrepancies between MIC and MLC values of amphotericin B against isolates of Aspergillus species | Q49204068 |
| | Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: reliability of relatively high doses administered over a relatively short period | Q49295342 |
| | Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. | Q52073846 |
| | Amphotericin B in the treatment of coccidioidomycosis. | Q53787658 |
| | Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. | Q54049140 |
| | Beneficial Effect of Recombinant Human Granulocyte Colony-Stimulating Factor on Fungicidal Activity of Polymorphonuclear Leukocytes from Patients with AIDS | Q58864148 |
| | A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group | Q68062081 |
| | In-vitro activity of SCH39304 in comparison with amphotericin B and fluconazole | Q68760517 |
| | Infectious complications in adults with bone marrow transplantation and T-cell depletion of donor marrow. Increased susceptibility to fungal infections | Q68871084 |
| | Amphotericin B-induced oxidative damage and killing of Candida albicans | Q68878670 |
| | Inactivation of amphotericin B by reducing agents: Influences on growth inhibition ofCandida albicansand lysis of erythrocytes | Q69188412 |
| | Cryptococcosis in the acquired immunodeficiency syndrome | Q69907540 |
| | Treatment of murine histoplasmosis with UK 49,858 (fluconazole) | Q70149985 |
| | Fluconazole therapy for coccidioidal meningitis. The NIAID-Mycoses Study Group | Q70729597 |
| | Azole drug resistance as a cause of clinical relapse in AIDS patients with cryptococcal meningitis | Q70862795 |
| | Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group | Q71114944 |
| | Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing | Q71608312 |
| | Non-Candida fungal infections after bone marrow transplantation: risk factors and outcome | Q72029113 |
| | Coccidioidomycosis | Q72649535 |
| | Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer | Q72675254 |
| P433 | issue | 1 | |
| P304 | page(s) | 42-50 | |
| P577 | publication date | 1997-01-01 | |
| P1433 | published in | European Journal of Clinical Microbiology & Infectious Diseases | Q15754378 |
| P1476 | title | Key issues concerning fungistatic versus fungicidal drugs | |
| P478 | volume | 16 | |